Financial Performance - Total revenue for Q3 2025 was $22.6 million, a 31% increase from $17.2 million in Q3 2024[3] - Product revenue in Q3 2025 was $17.0 million, up 28% from $13.3 million in Q3 2024[3] - Subscription revenue for Q3 2025 reached $5.6 million, representing a 44% increase from $3.9 million in Q3 2024[3] - Gross profit for Q3 2025 was $19.9 million, with a gross margin of 88%, compared to 87% in Q3 2024[4] - Operating expenses in Q3 2025 were $34.6 million, a 39% increase from $24.9 million in Q3 2024[5] - Net loss for Q3 2025 was $13.5 million, or $0.37 per share, compared to a net loss of $10.4 million, or $1.85 per share, in Q3 2024[6] Cash and Guidance - Cash, cash equivalents, and marketable securities totaled $168.5 million as of September 30, 2025[6] - Ceribell raised its revenue guidance for the full year 2025 to a range of $87 million to $89 million, indicating growth of approximately 33% to 36% over the previous year[7] Market Position and Strategy - The company ended Q3 2025 with 615 total active accounts[8] - Ceribell aims to establish point-of-care EEG as a new standard of care for seizure management, targeting a $2 billion addressable market opportunity[2]
CeriBell, Inc.(CBLL) - 2025 Q3 - Quarterly Results